The DOI matches its Crossref record.
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration
Open accessAbstract
To determine the effects of IL-10 on cytokine and granulocyte responses during endotoxemia, two groups of eight healthy male volunteers were challenged with endotoxin (4 ng/kg) on two occasions, once in combination with placebo injection, and once in conjunction with i.v. administered recombinant human IL-10 (rhIL-10) (25 microg/kg). In group 1, rhIL-10 was administered 2 min before endotoxin challenge; in group 2, the intervention was delayed for 1 h after endotoxin administration. rhIL-10 pretreatment reduced the LPS-induced rises in temperature and release of TNF, IL-6, IL-8, and IL-1 receptor antagonist. Endotoxin-induced granulocyte accumulation in lungs, as determined by dynamic granuloscintigrams, was prevented by rhIL-10 pretreatment, whereas granulocyte recruitment in liver and spleen was only modestly reduced. In addition, granulocyte degranulation, as measured by plasma elastase/alpha1-antitrypsin complexes, was blunted significantly by rhIL-10 pretreatment. Post-treatment with rhIL-10 did not influence LPS-induced temperature responses, cytokine release, or granulocyte degranulation. Both rhIL-10 pretreatment and post-treatment reduced LPS-induced cortisol levels. These results indicate that pretreatment with rhIL-10 reduces endotoxin-induced febrile responses, cytokine responses, and granulocyte accumulation in lungs, while in this acute model post-treatment with rhIL-10 exerts limited anti-inflammatory effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Opal, S. M., & DePalo, V. A. (2000) · Chest · doi:10.1378/chest.117.4.1162 · Cited by 1,752
Interleukin-10 Therapy—Review of a New Approach
Asadullah, K., Sterry, W., & Volk, H. D. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.4 · Cited by 946
Hu, X., & Ivashkiv, L. B. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.002 · Cited by 928
Mocellin, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00009-1 · Cited by 463
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
Schreiber, S., Fedorak, R. N., Nielsen, O. H., Wild, G., Williams, C. N., Nikolaus, S., Jacyna, M., Lashner, B. A., Gangl, A., Rutgeerts, P., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.20196 · Cited by 458
Self-citationIL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury
Deng, J., Kohda, Y., Chiao, H., Wang, Y., Hu, X., Hewitt, S. M., Miyaji, T., Mcleroy, P., Nibhanupudy, B., Li, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00043.x · Cited by 399
New Insights into the Biology of the Acute Phase Response
Suffredini, A. F., Fantuzzi, G., Badolato, R., Oppenheim, J. J., & O'Grady, N. P. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020563913045 · Cited by 391
van der Sluijs, K. F., van Elden, L. J. R., Nijhuis, M., Schuurman, R., Pater, J. M., Florquin, S., Goldman, M., Jansen, H. M., Lutter, R., & van der Poll, T. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7603 · Cited by 334
Self-citationAntipyretics: mechanisms of action and clinical use in fever suppression
Aronoff, D. M., & Neilson, E. G. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00834-8 · Cited by 326
CYTOKINES AND ANTICYTOKINES IN THE PATHOGENESIS OF SEPSIS
van der Poll, T., & van Deventer, S. J. H. (1999) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70083-0 · Cited by 323
Self-citationProinflammatory Effects of IL-10 During Human Endotoxemia
Lauw, F. N., Pajkrt, D., Hack, C. E., Kurimoto, M., van Deventer, S. J. H., & van der Poll, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2783 · Cited by 318
Self-citationSuppression of antigen presentation by IL-10
Mittal, S. K., & Roche, P. A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.12.009 · Cited by 314
Hu, X., Chakravarty, S. D., & Ivashkiv, L. B. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00707.x · Cited by 303
Oberholzer, A., Oberholzer, C., & Moldawer, L. L. (2002) · Critical Care Medicine · doi:10.1097/00003246-200201001-00008 · Cited by 298
Kox, M., van Eijk, L. T., Zwaag, J., van den Wildenberg, J., Sweep, F. C. G. J., van der Hoeven, J. G., & Pickkers, P. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322174111 · Cited by 268
Reversing Lipopolysaccharide Toxicity by Ligating the Macrophage Fcγ Receptors
Gerber, J. S., & Mosser, D. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6861 · Cited by 263
The two faces of interleukin 10 in human infectious diseases
Mege, J.-L., Meghari, S., Honstettre, A., Capo, C., & Raoult, D. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70577-1 · Cited by 257
Geerts, S. O., Nys, M., De Mol, P., Charpentier, J., Albert, A., Legrand, V., & Rompen, E. H. (2002) · Journal of Periodontology · doi:10.1902/jop.2002.73.1.73 · Cited by 257
Interleukin-10 potential benefits and possible risks in clinical infectious diseases
Opal, S. M., Wherry, J. C., & Grint, P. (1998) · Clinical Infectious Diseases · doi:10.1086/515032 · Cited by 114
Bahador, M., & Cross, A. S. (2007) · Journal of Endotoxin Research · doi:10.1177/0968051907085986 · Cited by 108
“In addition, rNAPc2 attenuated the endotoxin-induced rise in IL-10, without affecting the increase in other cytokines Study Pajkrt et al. (1997)171 Subjects Two groups, each 8 M Inhibitor rhIL-10 or placebo Objective To determine the effects of IL-10 on LPS-induced activation of the hemostatic…”
Background
Metadata
- Authors
- Pajkrt, D., Camoglio, L., Tiel-van Buul, M. C., de Bruin, K., Cutler, D. L., Affrime, M. B., Rikken, G., van der Poll, T., ten Cate, J. W., & van Deventer, S. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-04
- Volume
- 158
- Issue
- 8
- Pages
- 3971-3977
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2141608117
- Cited by
- 196
- References
- 0
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.